Anagliptin vs Yogliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Anagliptin · Suiny
Marketed by Sanwa Kagaku Kenkyusho and partners
NCT01529541 · Phase 3 · completed
The study randomly assigned an estimated 200 participants and used triple masking with sitagliptin as an active comparator. Its primary endpoint was the change in HbA1c, a surrogate measure, and no primary-outcome result is available to show whether the comparison was favorable.
Next expected readout: March 2027 · NCT07442006 (registry estimate)
Reported efficacy
The Change in HbA1c from baseline to week24 (0wk, 8wk, 16wk, 24wk): HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo. (met)
Result source: NCT01529528
Yogliptin
Developed by Chengdu Easton Biopharmaceuticals
NCT05318326 · Phase 3 · status unknown
The trial randomly assigns patients to Yogliptin or a matching placebo and blinds patients, care providers, investigators and outcome assessors alike, using HbA1c change, the standard regulator-accepted measure for diabetes drugs, as its main result. Results have not been posted yet, so whether Yogliptin lowered blood sugar significantly more than placebo is not yet known.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Anagliptin | Yogliptin |
|---|---|---|
| HbA1c, change | -0.5% vs 0.2%a−0.7 vs placeboNCT015295282 other results
| —Not reported |
| Body weight, change (kg) | —Not posted · NCT01529528 | —Not reported |
| HbA1c below 7% | —Not posted · NCT01529528 | —Not reported |
| Fasting plasma glucose, change | —Not posted · NCT01529528 | —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT01529528 | —Not reported |
HbA1c, change
- Anagliptin
- -0.5% vs 0.2%a−0.7 vs placeboNCT01529528
2 other results
- -0.5% vs 0.2% NCT01529528
- -0.8% vs -0.8% NCT01529541
- Yogliptin
- —Not reported
Body weight, change (kg)
- Anagliptin
- —Not posted · NCT01529528
- Yogliptin
- —Not reported
HbA1c below 7%
- Anagliptin
- —Not posted · NCT01529528
- Yogliptin
- —Not reported
Fasting plasma glucose, change
- Anagliptin
- —Not posted · NCT01529528
- Yogliptin
- —Not reported
3-point MACE (% with event)
- Anagliptin
- —Not posted · NCT01529528
- Yogliptin
- —Not reported
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Yogliptin: no structured comparison results are available for Type 2 Diabetes.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Anagliptin
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anagliptin's landscape · Yogliptin's landscape